Estrogen is a family of related steroid hormones, not a single molecule. Three matter clinically — estradiol (E2), estrone (E1), and estriol (E3) — and one of them, estradiol, does almost all the heavy lifting outside of pregnancy. It is made primarily in the ovaries during reproductive years, in the placenta during pregnancy, and in peripheral tissues (especially fat) via aromatase throughout life. Men produce meaningful amounts too, and their biology depends on it.
At a glance
What it does
In women, estradiol drives pubertal development of breasts, uterus, and secondary sex characteristics, regulates the menstrual cycle, prepares the endometrium for implantation, and coordinates with progesterone to sustain pregnancy. Outside reproduction, estradiol supports bone density by restraining osteoclast activity, improves endothelial function and lipid profiles, modulates thermoregulation (its loss in menopause produces hot flashes), influences mood and cognition, maintains vaginal and urethral tissue, and shapes skin thickness and collagen.
In men, estradiol is often mispictured as a "female hormone leaking into men." Wrong. Men produce estradiol continuously by aromatizing testosterone in fat, brain, bone, and testis itself, and male tissues depend on it. Estradiol is critical for male bone density — men lacking aromatase or the estrogen receptor develop severe osteoporosis despite normal testosterone — and contributes to male libido, vascular health, and regulation of fat distribution. Crushing male estradiol with aromatase inhibitors, as some TRT patients and bodybuilders do, causes joint pain, bone loss, and tanked libido.
The three estrogens differ in potency and role. Estradiol is the most potent, dominant during reproductive years. Estrone is weaker and becomes the dominant circulating estrogen after menopause (made in fat tissue). Estriol is the weakest, mostly relevant during pregnancy where the fetoplacental unit produces it in large amounts.
How it works
Production in women follows the menstrual cycle. The hypothalamus pulses GnRH; the pituitary releases FSH and LH; FSH stimulates granulosa cells in developing ovarian follicles to aromatize androgens (from theca cells) into estradiol. Estradiol rises through the follicular phase, feeds back to trigger the LH surge that causes ovulation, then falls before the corpus luteum takes over progesterone production during the luteal phase. If no pregnancy occurs, the corpus luteum dies, estradiol and progesterone crash, and menstruation follows.
In men, aromatase converts testosterone to estradiol continuously in multiple tissues. Visceral and subcutaneous fat express aromatase strongly, which is why obese men have disproportionately high estradiol and low testosterone — the substrate gets diverted. Brain aromatase produces local estradiol for neural effects. Testicular aromatase in Leydig and Sertoli cells contributes to systemic levels.
Estrogens act on two main nuclear receptors, ER-alpha and ER-beta, expressed in different patterns across tissues. This is why tissue-selective estrogen receptor modulators (SERMs) like tamoxifen can antagonize ER in breast tissue while agonizing it in bone — the receptor subtype distribution determines the drug's local behavior. Estradiol also acts rapidly through membrane-associated receptors for some cardiovascular and neural effects before genomic signaling kicks in.
Like testosterone, estradiol circulates largely bound. Roughly 37% binds SHBG tightly, about 61% binds albumin loosely, and only 1-2% is free. Free estradiol is the bioavailable fraction, though most clinical labs report only total E2. This is why SHBG matters when interpreting estrogen labs in both sexes.
Levels & ranges
Women's estradiol swings dramatically across the menstrual cycle. Early follicular: 30-100 pg/mL. Pre-ovulatory peak: 200-400 pg/mL. Mid-luteal: 70-250 pg/mL. A single measurement out of context is almost meaningless — interpretation requires knowing where in the cycle the draw happened, or doing serial draws. During pregnancy, estradiol rises into the thousands of pg/mL, driven by placental production.
In men, normal estradiol runs roughly 10-40 pg/mL. Above 60-70 pg/mL in men often signals obesity-driven aromatization, anabolic steroid use, or an estradiol-secreting tumor. Below 10-15 pg/mL is associated with joint pain, libido drop, and bone loss — commonly seen in men who overuse aromatase inhibitors while on TRT.
Postmenopausal women typically show estradiol below 20 pg/mL, sometimes below assay detection limits. Estrone becomes the more abundant circulating estrogen, produced in fat tissue. This is why body fat correlates with postmenopausal breast cancer risk — ongoing estrogen exposure from adipose aromatase drives hormone-sensitive tumor growth.
Assay matters. Immunoassays for estradiol are notoriously unreliable at low male and postmenopausal concentrations; liquid chromatography-mass spectrometry (LC-MS/MS) is the gold standard and is what you want if a precise low-range estradiol is clinically important.
When it goes wrong
Estrogen deficiency in women before menopause causes amenorrhea, infertility, low libido, vaginal atrophy, bone loss, and elevated cardiovascular risk. Causes include premature ovarian insufficiency, functional hypothalamic amenorrhea (energy deficit, overtraining, stress, low body fat), and surgical menopause from oophorectomy. Menopause itself is the universal eventual cause, hitting a median age of 51 in the US.
Menopause symptoms — hot flashes, night sweats, sleep disruption, mood shifts, vaginal dryness, urinary symptoms, accelerating bone loss — are mostly estradiol-withdrawal phenomena, not aging per se. The Women's Health Initiative scared a generation of women off hormone therapy with an overinterpreted 2002 analysis. The more recent nuanced reading is that starting estrogen within 10 years of menopause or before age 60, for symptomatic women without strong contraindications, produces more benefit than harm for most and is almost always the right answer for moderate-to-severe symptoms.
Estrogen excess in women is tied to obesity, anovulatory cycles, and certain tumors, and drives hormone-sensitive cancers (breast, endometrial). Unopposed estrogen (without progesterone) on the endometrium is the classic carcinogenic pattern — this is why women with a uterus on systemic estrogen therapy need progestin.
In men, excess estradiol (usually from obesity, exogenous aromatizing steroids, or advanced liver disease) causes gynecomastia, water retention, reduced libido, and emotional lability. Deficient estradiol in men causes bone loss, joint pain, and paradoxically reduced libido. The idea that crushing estrogen makes men more "manly" is one of the most persistent and damaging myths in bodybuilding circles.
Interactions
Body fat is the biggest modulator outside the gonads themselves. Adipose aromatase converts androgens to estrogens, so high body fat raises estrogen (especially in men and postmenopausal women) and lower body fat reduces it (a major reason extremely lean female athletes lose periods). Alcohol raises estradiol in both sexes by interfering with hepatic clearance and possibly raising aromatase. Hormonal contraceptives deliver synthetic estrogens (typically ethinyl estradiol) that override the endogenous cycle. Menopause hormone therapy uses estradiol (oral, transdermal, or vaginal) alone or with progesterone, depending on whether the uterus is still present.
SSRIs and SNRIs reduce hot flash frequency in menopause, though less effectively than estrogen. Aromatase inhibitors (anastrozole, letrozole, exemestane) are central to treating estrogen receptor-positive breast cancer and are used cautiously in men on TRT with persistently high E2 and symptoms. SERMs (tamoxifen, raloxifene) block estrogen in breast tissue while preserving or agonizing it elsewhere. Grapefruit and certain drugs that inhibit CYP3A4 can raise estrogen levels by slowing hepatic clearance.
Honest take
The post-WHI backlash against menopause hormone therapy has caused measurable harm to a generation of women — untreated vasomotor symptoms, accelerated bone loss, sleep disruption, and an unquantifiable quality-of-life hit. For symptomatic women within 10 years of menopause and without specific contraindications (recent breast cancer, unexplained vaginal bleeding, prior VTE or stroke), transdermal estradiol with cyclic or continuous progesterone is a reasonable default worth discussing with an informed clinician. On the male side, aromatase inhibitor abuse in TRT and bodybuilding communities is underappreciated as a cause of joint pain, bone loss, and libido collapse — chasing a low estradiol number on a lab printout while feeling terrible is exactly the wrong move.
Sources
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society — the most current consensus on HT risk-benefit.
- Manson et al., WHI long-term follow-up, JAMA (2017) — the updated read on the original WHI findings.
- Finkelstein et al., NEJM (2013) — the study that demonstrated the role of estradiol in male body composition and sexual function by separating androgen and estrogen effects.
- Rochira & Carani, Nature Reviews Endocrinology — on male estrogen deficiency syndromes.